Sign in Subscribe
Medical equipment industry

Medtronic and Novo Nordisk Partner to Develop Prefilled Insulin Cartridges for Diabetic Patients

Strategic Insights

— 1 min read

The partnership between Medtronic and Novo Nordisk aims to simplify insulin pump therapy for diabetic patients by introducing prefilled insulin cartridges. The companies will develop prefilled cartridges containing U-100 NovoLog(R) (insulin aspart (rDNA origin) injection) for use with Paradigm(R) external insulin pumps. This innovation is expected to eliminate the need for manual insulin transfer, making pump therapy more convenient and simplifying the treatment process for diabetic patients.

Key Takeaways:

  • Medtronic and Novo Nordisk have partnered to develop prefilled insulin cartridges for Paradigm(R) pump therapy, simplifying insulin pump treatment for diabetic patients.
  • The prefilled cartridges will contain U-100 NovoLog(R) (insulin aspart (rDNA origin) injection) and eliminate the need for manual insulin transfer.
  • The companies will conduct clinical studies to demonstrate the advantages of NovoLog insulin and Paradigm pump therapy over other insulin therapies.
  • The partners will create medical education initiatives highlighting the importance of maintaining target A1C of less than 7.0 percent to improve long-term glycemic control.
  • Pump therapy is a proven method of maintaining tight glucose control, and Medtronic's Diabetes business is the world leader in insulin pump therapy and continuous glucose monitoring.
  • Novo Nordisk is a world leader in diabetes care with a broad diabetes product portfolio, including the most advanced products within insulin delivery systems.

Statistics:

  • Over 420 million people worldwide have diabetes, making it a major public health concern (Source: International Diabetes Federation).
  • Diabetes is the leading cause of blindness, kidney failure, amputation, impotence, stroke, and heart disease (Source: Centers for Disease Control and Prevention).
  • Insulin pumps use only short- or rapid-acting insulin and deliver small, continuous doses (basal) around the clock, as well as extra insulin (bolus) with meals (Source: Medtronic MiniMed).
  • Pump therapy allows patients to adjust their basal and bolus insulin doses according to activity and meals, providing greater flexibility and improved quality of life (Source: Medtronic MiniMed).
  • Novo Nordisk has approximately 20,000 full-time employees in 69 countries and markets its products in 179 countries (Source: Novo Nordisk).

Sources:

  • Medtronic. Diabetes Business Unit. (n.d.). Minimed.
  • Medtronic, Inc. (n.d.). About Us. Retrieved from www.medtronic.com
  • Novo Nordisk. (n.d.). About Us. Retrieved from www.novonordisk.com
  • International Diabetes Federation. (n.d.). Diabetes Atlas.
  • Centers for Disease Control and Prevention. (n.d.). Diabetes.

Read more